Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Sunshine Biopharma (SBFM) over the last 9 years, with Q3 2025 value amounting to -$118295.0.

  • Sunshine Biopharma's Cash from Investing Activities rose 8235.98% to -$118295.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 4302.51%. This contributed to the annual value of -$2.3 million for FY2024, which is 25370.68% down from last year.
  • Per Sunshine Biopharma's latest filing, its Cash from Investing Activities stood at -$118295.0 for Q3 2025, which was up 8235.98% from -$491778.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Cash from Investing Activities ranged from a high of $18859.0 in Q3 2023 and a low of -$14.6 million during Q4 2022
  • Its 4-year average for Cash from Investing Activities is -$1.5 million, with a median of -$354267.0 in 2023.
  • As far as peak fluctuations go, Sunshine Biopharma's Cash from Investing Activities soared by 9815.84% in 2023, and later tumbled by 365585.66% in 2024.
  • Over the past 4 years, Sunshine Biopharma's Cash from Investing Activities (Quarter) stood at -$14.6 million in 2022, then surged by 98.16% to -$269230.0 in 2023, then crashed by 63.17% to -$439304.0 in 2024, then surged by 73.07% to -$118295.0 in 2025.
  • Its Cash from Investing Activities stands at -$118295.0 for Q3 2025, versus -$491778.0 for Q2 2025 and -$176024.0 for Q1 2025.